Overview

Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields

Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
0
Participant gender:
All
Summary
The participants are being treated with Tumor Treating Fields (TTFields) for malignant glioma, and this type of treatment may cause skin-related side effects. This study will test whether using clindamycin and triamcinolone topical lotions can prevent skin-related side effects of TTFields.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Treatments:
Clindamycin
Clindamycin palmitate
Clindamycin phosphate
Triamcinolone
Triamcinolone Acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Criteria
Inclusion Criteria:

- Age ≥18 years

- Diagnosis of newly diagnosed GBM with plan to initiate treatment with TTFields with or
without systemic therapy, confirmed by the enrolling institution

- Able to self-administer topical interventions or has available another person who can
apply the topical agents

- Treatment with TTF should be initiated within 7 days of planned initiation on this
trial.

Exclusion Criteria:

- Known history of allergy to any ingredient of the study agents

- Preexisting scalp disorders such as psoriasis or dermatitis that, in the opinion of
the investigator, will affect the grading of skin adverse events, confirmed by
enrolling institution.

- Use of concurrent topical therapy to the scalp for another dermatologic condition

- Active, uncontrolled infection requiring systemic or oral antibiotic therapy within 14
days of enrollment

- Use of dexamethasone 2mg a day or greater within 14 days of enrollment

- Recurrent GBM or malignant glioma

- Concurrent administration of bevacizumab

- Pregnant Women